Metsera (NASDAQ:MTSR) Trading Down 6.9% – Here’s What Happened

Metsera, Inc. (NASDAQ:MTSR)’s share price fell 6.9% during mid-day trading on Friday . The stock traded as low as $25.47 and last traded at $25.70. 77,054 shares were traded during trading, a decline of 91% from the average session volume of 876,134 shares. The stock had previously closed at $27.59.

Analysts Set New Price Targets

Several brokerages recently issued reports on MTSR. Guggenheim began coverage on shares of Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price for the company. Evercore ISI began coverage on shares of Metsera in a report on Tuesday, February 25th. They set an “outperform” rating for the company. Cantor Fitzgerald began coverage on shares of Metsera in a report on Tuesday, February 25th. They set an “overweight” rating for the company. Finally, Bank of America started coverage on shares of Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price for the company.

Metsera Trading Down 3.9%

The business’s fifty day simple moving average is $22.88.

Metsera (NASDAQ:MTSR) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MTSR. Alphabet Inc. purchased a new position in Metsera in the first quarter valued at $135,059,000. T. Rowe Price Investment Management Inc. purchased a new position in Metsera in the first quarter valued at $78,748,000. Wellington Management Group LLP acquired a new stake in shares of Metsera in the first quarter valued at about $65,382,000. Alpha Wave Global LP acquired a new stake in shares of Metsera in the first quarter valued at about $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Metsera in the first quarter valued at about $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.